nature portfolio

https://doi.org/10.1038/s41591-021-01462-y

Supplementary information

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

In the format provided by the authors and unedited

Supplementary Information: Tumor-infiltrating lymphocyte treatment for anti-PD-1 resistant metastatic lung cancer: a phase I trial

Ben C. Creelan, Chao Wang , Jamie K. Teer, Eric M. Toloza, Jiqiang Yao, Sungjune Kim, Ana M. Landin, John E. Mullinax, James J. Saller , Andreas N. Saltos , David R. Noyes M.S., Leighann B. Montoya, Wesley Curry, Shari A. Pilon-Thomas, Alberto A. Chiappori, Tawee T. Tanvetyanon, Frederick J. Kaye, Zachary J Thompson, Sean J. Yoder, Bin Fang, John M. Koomen, Amod A. Sarnaik, Dung-Tsa Chen, Jose R. Conejo-Garcia, Eric B. Haura, Scott J. Antonia.

Table of Contents

Supplementary Table 1: Baseline characteristics of all enrolled patients.

ID	Histology	Age	Sex	PD-L1 TPS	F1 TMB mut/MB	WES TMB mut/MB	Smoking pack-years	Driver oncogene(s)	Harvested Metastasis	Prior Therapy	Infused w/ TIL	BOR w/ TIL
01	Adenocarcinoma	48	M	11%	0.8	0.4	0	*CCDC6-RET*	Supraclavicular LN	None	Y	SD
02	Adenocarcinoma	54	M	0%	9	5.2	30	*KRAS* G12V	Supraclavicular LN	Carboplatin and pemetrexed	Y	uPR
03	Adenocarcinoma	69	F	0%	1	1.4	1.2	*EGFR* Ex20 ins	Paratracheal LN	RT	Y	NE
04	Adenosquamous	44	F	85%	3	0.7	0	*CD74-ROS1*	Supraclavicular LN	Crizotinib*	Y	PD
05	Adenocarcinoma	63	F	1%	4	1.9	17.5	*KRAS* G12C	Pleural nodule	None	Y	uPR
07	Adenocarcinoma	49	F	0%	4	1.5	0	*EGFR* L861Q	Pleural nodule	None*	Y	SD
08	Squamous	49	M	0%	5	1.2	0	None	Axillary LN	RT	Y	SD
09	Adenocarcinoma	56	F	10%	25	10.2	30	None	Supraclavicular LN	None	Y	CR
12	Adenocarcinoma	50	F	20%	4	0.1	0	*EML4-ALK*	Pleural nodule	None*	N	--
13	Squamous	69	F	17%	18	4.6	40	None	Lung nodule	None	Y	NE
14	Adenocarcinoma	53	F	100%	16	8.1	34	None	Supraclavicular LN	Carboplatin and paclitaxel, SBRT	Y	PD
15	Adenocarcinoma	75	M	0%	3	1.1	25	*KRAS* G12C	Pleural nodule	None	Y	NE
16	Squamous	66	M	0%	7	1.5	0	None	Pleural nodule	Carboplatin and paclitaxel	Y	PR
25	Adenocarcinoma	61	F	2%	6	2.1	0	*EGFR* Ex19 del	Pleural nodule	Afatinib, osimertinib	Y	CR
26	Squamous	60	M	80%	15	7.5	40	*PI3CKA* H1047R	Chest wall met	Cisplatin VP16, carboplatin paclitaxel	N	--
29	Adenocarcinoma	45	M	90%	5	1.6	32	*KRAS* G12C	Supraclavicular LN	None	N	--
30	Adenocarcinoma	38	M	100%	2.5	2.4	0	*EML4-ALK* fusion	Cervical LN	Cisplatin and pemetrexed,	N	--
31	Adenocarcinoma	69	M	97%	6	2.1	40	*KRAS* G12V	Pleural nodule	None	Y	uPR
32	Adenocarcinoma	45	F	0%	3	1.3	0	*EGFR* Ex19 del	Pleural nodule	Osimertinib	Y	PD
33	Squamous	42	M	0%	1	0.5	0	*EWSR1-CREM*	Pleural nodule	None	Y	SD
Median:		54		6%	4.5	1.5	9	--	--	0-1		

Footnotes: Abbreviations: TPS denotes tumor proportion-score by 22C3 PD-L1 score; LN, lymph node; TMB; estimated tumor mutation burden; F1, mutation burden estimated by Foundation One; WES, mutation burden calculated by whole-exome sequencing; RT, radiation; SBXRT, stereotactic body radiation; TIL, tumor-infiltrating lymphocytes; BOR, best overall response type; SD, stable disease; uPR, unconfirmed partial response; NE, not evaluable; CR, complete response; PD, progressive disease; and mut/MB, mutations per megabase.

*Indicates patient with initial negative testing for ALK or EGFR by plasma and/or FISH testing, only identified after next-generation sequencing of excised tumor after enrollment

Supplementary Table 2: Correlative assays performed by subject ID.*

ID	PD-L1 IHC	Tumor WES	Tumor RNAseq	Tumor TCRseq	TIL Culture	PBMC test NeoAgs	TIL test NeoAgs	Tumor FMI CDx	FEST testing	IsoCode Cytokine
01	Y	Y	Y	Y	Y	Y	Y	Y	N	Y
02	Y	Y	Y	Y	Y	Y	N§	Y	Y	Y
03	Y	Y	Y	Y	Y	Y	Y	Y	N	Y
04	Y	Y	Y	Y	Y	Y	Y	Y	N	Y
05	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
07	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
08	Y	Y	Y	Y	Y	Y	Y	Y	N	Y
09	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
12	Y	Y	Y	Y	Y^	Y	Y	Y	N	Y
13	Y	Y	Y	Y	Y	Y	Y	Y	N	Y
14	Y	Y	Y	Y	Y	Y	Y	Y	N	Y
15	Y	Y	Y	Y	Y	Y	Y	Y	N	Y
16	Y	Y	Y	Y	Y	Y	Y	Y	Y	N
25	Y	Y	Y	Y	Y	Y	N§	Y	Y	N
26	Y	Y	Y	Y	Y	Y	Y	Y	N	N
29	Y	Y	Y	Y	Y	Y	Y	Y	N	N
30	Y	Y	Y	Y	Y	Y	Y	Y	N	N
31	Y	Y	Y	Y	Y	Y	Y	Y	Y	N
32	Y	Y	Y	Y	Y	Y	N§	Y	N	N
33	Y	Y	Y	Y	Y	Y	N§	Y	N	N

**Footnotes*: ^Cultured TIL used for research but insufficient for clinical production. § For these patients, TIL has too much background IFN-γ reactivity to interpret ELISpot data. Abbreviations: IHC; immunohistochemistry. WES; whole-exome sequencing. FEST; Functional Expansion of Specific T Cells[3]; FMI, Foundation CDx.

Appendix 1

RE: Adverse Events Report for each patient: Phase I Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced NSCLC (MCC 19122)
Date: February 10, 2021
To: Ben Creelan
From: Zachary Thompson, Dung-Tsa Chen
Contact: Zachary Thompson, zachary.thompson@moffitt.org Dung-Tsa Chen, Dung-Tsa.Chen@moffitt.org

List of Tables

1 Each patient separately

Table 1: Adverse events for patient 001

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
001	Alanine aminotransferase increased	2	0	0	0	0
	Alkaline phosphatase increased	1	0	0	0	0
	Anemia	1	0	0	0	0
	Anorexia	1	0	0	0	0
	Aspartate aminotransferase increased	1	0	0	0	0
	Dehydration	1	0	0	0	0
	Depression	1	0	0	0	0
	Edema limbs	1	0	0	0	0
	Fatigue	1	0	0	0	0
	Fever	2	0	0	0	0
	Hyperkalemia	1	0	0	0	0
	Hypermagnesemia	1	0	0	0	0
	Hypoalbuminemia	2	1	0	0	0
	Hypocalcemia	1	0	0	0	0
	Hyponatremia	1	0	0	0	0
	Hypophosphatemia	0	0	1	0	0
	Lymphocyte count decreased	0	0	2	1	0
	Nausea	1	0	0	0	0
	Neutrophil count decreased	1	1	1	1	0
	Platelet count decreased	2	0	1	0	0
	Rash	2	0	0	0	0
	Sinus tachycardia	1	0	0	0	0
	Urinary incontinence	1	0	0	0	0
	White blood cell decreased	1	1	1	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 2: Adverse events for patient 002

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
002	Abdominal pain	1	0	0	0	0
	Alanine aminotransferase increased	2	0	0	0	0
	Alkaline phosphatase increased	3	1	0	0	0
	Anemia	0	4	2	0	0
	Aspartate aminotransferase increased	1	0	0	0	0
	Blood bilirubin increased	2	0	0	0	0
	Chills	1	0	0	0	0
	Constipation	1	0	0	0	0
	Creatinine increased	1	0	0	0	0
	Dehydration	1	0	0	0	0
	Diarrhea	2	2	0	0	0
	Dysgeusia	1	0	0	0	0
	Dysphagia	1	0	0	0	0
	Electrocardiogram QT corrected interval prolonged	1	0	0	0	0
	Fever	3	1	2	0	0
	Gastritis	0	1	0	0	0
	Hyperkalemia	2	0	0	0	0
	Hypermagnesemia	1	0	0	0	0
	Hypoalbuminemia	2	1	0	0	0
	Hypocalcemia	1	1	0	0	0
	Hyponatremia	2	0	0	0	0
	Hypophosphatemia	0	1	4	0	0
	INR increased	1	0	0	0	0
	Lymphocyte count decreased	1	0	3	3	0
	Mucositis oral	1	0	0	0	0
	Nausea	2	0	0	0	0
	Neutrophil count decreased	1	1	0	1	0
	Non-cardiac chest pain	0	1	0	0	0
	Pain	0	1	0	0	0
	Platelet count decreased	3	2	1	1	0
	Pulmonary edema	0	0	0	1	0
	Rash	1	0	0	0	0
	Respiratory, thoracic and mediastinal disorders	0	1	0	0	0
	Urinary urgency	1	0	0	0	0
	Vomiting	1	0	0	0	0
	White blood cell decreased	4	3	1	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 3: Adverse events for patient 003

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
003	Acute kidney injury	0	1	0	0	0
	Alkaline phosphatase increased	1	0	0	0	0
	Anemia	3	4	3	0	0
	Creatinine increased	0	0	1	0	0
	Dry eye	1	0	0	0	0
	Dry mouth	1	0	0	0	0
	Dysphagia	1	0	0	0	0
	Eye disorders	2	0	0	0	0
	Hyperkalemia	1	0	0	0	0
	Hypermagnesemia	1	0	0	0	0
	Hypoalbuminemia	3	1	0	0	0
	Hypocalcemia	3	0	0	0	0
	Hyponatremia	2	0	0	0	0
	Hypophosphatemia	0	1	2	0	0
	Hypothyroidism	0	1	0	0	0
	INR increased	1	0	0	0	0
	Lymphocyte count decreased	1	0	2	1	0
	Neutrophil count decreased	0	1	0	0	0
	Pain	1	0	0	0	0
	Platelet count decreased	1	1	2	1	0
	Postnasal drip	1	0	0	0	0
	Rash	2	0	0	0	0
	White blood cell decreased	3	1	1	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 4: Adverse events for patient 004

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
004	Anemia	1	4	3	0	0
	Aspartate aminotransferase increased	1	0	0	0	0
	Chills	1	0	0	0	0
	Diarrhea	2	0	0	0	0
	Dyspnea	0	1	0	0	0
	Fever	3	1	0	0	0
	Hypoalbuminemia	1	1	0	0	0
	Hypocalcemia	1	0	0	0	0
	Hypokalemia	1	0	0	0	0
	Hypophosphatemia	0	1	2	0	0
	Hypotension	1	0	0	0	0
	Hypoxia	0	1	0	0	0
	Lymphocyte count decreased	2	4	4	1	0
	Menorrhagia	1	0	0	0	0
	Nausea	0	1	0	0	0
	Neutrophil count decreased	0	0	0	1	0
	Platelet count decreased	3	2	3	2	0
	Rash	1	0	0	0	0
	Sinus tachycardia	1	0	0	0	0
	White blood cell decreased	1	0	0	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 5: Adverse events for patient 005

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
005	Anemia	0	1	0	0	0
	Chills	1	0	0	0	0
	Dizziness	0	1	0	0	0
	Edema limbs	0	1	0	0	0
	Headache	0	1	0	0	0
	Hypoalbuminemia	0	1	0	0	0
	Hyponatremia	1	0	0	0	0
	Hypophosphatemia	0	1	0	0	0
	Hypotension	0	1	0	0	0
	Hypoxia	0	1	0	0	0
	Infections and infestations	0	1	0	0	0
	Lung infection	0	0	1	0	0
	Lymphocyte count decreased	0	3	3	3	0
	Neutrophil count decreased	0	0	0	1	0
	Rash	1	0	0	0	0
	Tremor	1	0	0	0	0
	Urinary tract infection	0	2	0	0	0
	Weight loss	0	1	0	0	0
	Wheezing	1	0	0	0	0
	White blood cell decreased	1	0	1	0	0

Note:

Possible, Probable, or Definite Attribution Only

Table 6: Adverse events for patient 007

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
007	Alanine aminotransferase increased	1	0	0	0	0
	Anemia	0	1	2	0	0
	Anorexia	0	1	0	0	0
	Aspartate aminotransferase increased	0	0	1	0	0
	Diarrhea	1	0	0	0	0
	Dizziness	1	0	0	0	0
	Dry mouth	1	0	0	0	0
	Dyspepsia	0	1	0	0	0
	Edema limbs	1	0	0	0	0
	Fever	0	1	0	0	0
	Hyperglycemia	1	0	0	0	0
	Hyperkalemia	1	0	0	0	0
	Hypoalbuminemia	1	0	1	0	0
	Irregular menstruation	2	0	0	0	0
	Joint effusion	0	1	0	0	0
	Lymphocyte count decreased	1	1	0	1	0
	Nausea	0	1	0	0	0
	Neutrophil count decreased	0	1	1	2	0
	Pain	1	0	0	0	0
	Platelet count decreased	2	2	2	1	0
	Rash	0	1	0	0	0
	Sinus tachycardia	0	1	0	0	0
	Sore throat	1	0	0	0	0
	White blood cell decreased	2	0	0	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 7: Adverse events for patient 008

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
008	Acute kidney injury	0	1	0	0	0
	Alanine aminotransferase increased	5	2	0	0	0
	Alkaline phosphatase increased	0	0	1	0	0
	Anemia	0	1	0	0	0
	Aspartate aminotransferase increased	5	0	0	0	0
	Diarrhea	1	0	0	0	0
	Dry mouth	1	0	0	0	0
	Dyspnea	0	1	0	0	0
	Fever	1	0	0	0	0
	Gastritis	0	1	0	0	0
	Headache	1	0	0	0	0
	Hyperkalemia	1	0	0	0	0
	Hypoalbuminemia	1	1	0	0	0
	Hypocalcemia	2	0	0	0	0
	Hyponatremia	1	0	0	0	0
	Hypophosphatemia	0	0	1	0	0
	Hypotension	0	1	0	0	0
	INR increased	1	1	0	0	0
	Lymphocyte count decreased	4	1	0	1	0
	Nausea	1	0	0	0	0
	Platelet count decreased	2	1	1	0	0
	Rash	3	1	0	0	0
	Sinus tachycardia	1	1	0	0	0
	White blood cell decreased	0	2	0	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 8: Adverse events for patient 009

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
009	Alanine aminotransferase increased	0	1	0	0	0
	Alkaline phosphatase increased	1	0	0	0	0
	Anemia	1	4	2	0	0
	Anorexia	1	0	0	0	0
	Arthralgia	1	1	0	0	0
	Aspartate aminotransferase increased	0	1	0	0	0
	Bone pain	1	0	0	0	0
	Chills	1	0	0	0	0
	Constipation	2	0	0	0	0
	Cough	2	0	0	0	0
	Creatinine increased	1	0	0	0	0
	Diarrhea	2	0	0	0	0
	Dizziness	1	0	0	0	0
	Dyspnea	0	1	0	0	0
	Edema limbs	0	1	0	0	0
	Endocrine disorders	2	0	0	0	0
	Fever	0	1	0	0	0
	Headache	1	0	0	0	0
	Hyperglycemia	1	0	0	0	0
	Hypoalbuminemia	0	2	0	0	0
	Hypokalemia	2	0	0	0	0
	Hypophosphatemia	2	2	1	0	0
	Hypotension	2	1	0	0	0
	Hypoxia	1	1	0	0	0
	Lymphocyte count decreased	0	1	1	2	0
	Nausea	0	2	0	0	0
	Neutrophil count decreased	2	0	1	1	0
	Pain	0	2	0	0	0
	Peripheral sensory neuropathy	1	0	0	0	0
	Platelet count decreased	1	2	2	1	0
	Rash	1	0	0	0	0
	Respiratory, thoracic and mediastinal disorders	0	1	0	0	0
	Rhinitis infective	0	1	0	0	0
	Vasovagal reaction	0	0	1	0	0
	Vomiting	0	1	0	0	0
	White blood cell decreased	2	2	2	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 9: Adverse events for patient 012

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
012	Chills	1	0	0	0	0
	Edema limbs	1	0	0	0	0
	Fatigue	0	1	0	0	0
	Rash	2	0	0	0	0

Note:
Possible, Probable, or Definite Attribution Only

Table 10: Adverse events for patient 013

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
013	Alanine aminotransferase increased	0	1	0	0	0
	Alkaline phosphatase increased	0	1	0	0	0
	Anemia	0	3	1	0	0
	Anorexia	0	1	0	0	0
	Aspartate aminotransferase increased	1	0	1	0	0
	Cardiac disorders	1	0	0	0	0
	Chills	1	0	0	0	0
	Conjunctivitis	1	0	0	0	0
	Cytokine release syndrome	1	1	0	0	0
	Dehydration	0	1	0	0	0
	Diarrhea	1	1	0	0	0
	Dry mouth	1	0	0	0	0
	Dysphagia	0	1	0	0	0
	Dyspnea	1	0	1	0	0
	Febrile neutropenia	1	0	0	0	0
	Flu like symptoms	1	0	0	0	0
	Flushing	0	1	0	0	0
	Hot flashes	1	0	0	0	0
	Hypernatremia	1	0	0	0	0
	Hypoalbuminemia	1	2	0	0	0
	Hypocalcemia	4	2	1	0	0
	Hypokalemia	2	0	0	0	0
	Hyponatremia	0	0	1	0	0
	Hypophosphatemia	0	3	1	0	0
	Hypotension	0	1	0	0	0
	Hypoxia	0	1	0	0	0
	Lymphocyte count decreased	0	0	1	2	0
	Nausea	1	0	0	0	0
	Neutrophil count decreased	2	0	0	1	0
	Platelet count decreased	1	1	2	1	0
	Productive cough	0	1	0	0	0
	Pulmonary edema	0	1	0	0	0
	Rash	1	0	0	0	0
	Respiratory failure	0	0	0	1	0
	Respiratory, thoracic and mediastinal disorders	1	0	0	0	0
	Sinus tachycardia	1	1	0	0	0
	Stroke	0	0	0	1	1
	Urinary tract infection	1	0	0	0	0
	Vomiting	0	1	0	0	0
	White blood cell decreased	0	1	1	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 11: Adverse events for patient 014

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
014	Anemia	4	6	2	0	0
	Confusion	1	1	0	0	0
	Diarrhea	1	1	0	0	0
	Dizziness	1	0	0	0	0
	Dyspnea	0	1	0	0	0
	Edema limbs	0	1	0	0	0
	Febrile neutropenia	1	0	0	0	0
	Hyperglycemia	0	1	0	0	0
	Hyperthyroidism	1	0	0	0	0
	Hypoalbuminemia	2	1	0	0	0
	Hypocalcemia	1	0	0	0	0
	Hyponatremia	2	0	0	0	0
	Hypophosphatemia	0	1	0	0	0
	Hypotension	0	2	1	0	0
	Hypothyroidism	0	1	0	0	0
	Hypoxia	0	4	1	0	0
	Infections and infestations	1	0	0	0	0
	INR increased	1	0	0	0	0
	Lymphocyte count decreased	0	4	3	1	0
	Mucositis oral	1	0	0	0	0
	Nausea	0	1	0	0	0
	Neutrophil count decreased	1	1	1	1	0
	Platelet count decreased	3	2	3	2	0
	Pneumonitis	0	0	2	0	0
	Pulmonary edema	0	1	0	0	0
	Sinusitis	0	1	0	0	0
	White blood cell decreased	2	0	3	2	0

Note:

Possible, Probable, or Definite Attribution Only

Table 12: Adverse events for patient 015

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
015	Anemia	0	3	1	0	0
	Anorexia	0	1	0	0	0
	Blood bilirubin increased	2	0	0	0	0
	Bronchospasm	1	0	0	0	0
	Cardiac disorders	1	0	0	0	0
	Chills	1	0	0	0	0
	Dyspnea	1	1	0	0	0
	Hypoalbuminemia	1	1	0	0	0
	Hypokalemia	1	0	0	0	0
	Hypophosphatemia	0	1	1	0	0
	Hypotension	1	0	0	0	0
	Hypoxia	0	1	1	0	0
	Infusion related reaction	0	1	0	0	0
	Lymphocyte count decreased	0	1	0	1	0
	Nausea	0	1	0	0	0
	Neutrophil count decreased	0	0	1	0	0
	Pericarditis	0	1	0	0	0
	Platelet count decreased	0	1	1	1	0
	Pulmonary hypertension	0	1	0	0	0
	Respiratory failure	0	0	0	1	0
	Sinus tachycardia	1	1	0	0	0
	Stroke	0	1	0	0	0
	White blood cell decreased	2	0	0	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 13: Adverse events for patient 016

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
016	Alanine aminotransferase increased	1	0	0	0	0
	Anemia	4	5	1	0	0
	Anorexia	1	0	0	0	0
	Aspiration	0	0	1	0	0
	Chills	1	0	0	0	0
	Diarrhea	1	0	0	0	0
	Dry mouth	1	0	0	0	0
	Dysphagia	2	0	0	0	0
	Dyspnea	1	0	0	0	0
	Edema limbs	1	0	0	0	0
	Febrile neutropenia	1	0	0	0	0
	Gastrointestinal disorders	0	1	0	0	0
	Genital edema	1	0	0	0	0
	Hyperglycemia	0	3	2	1	0
	Hypertension	0	1	0	0	0
	Hypoalbuminemia	1	1	0	0	0
	Hypomagnesemia	2	0	0	0	0
	Hyponatremia	5	0	1	0	0
	Hypophosphatemia	0	3	0	0	0
	Hypoxia	1	0	0	0	0
	INR increased	1	0	0	0	0
	Lymphocyte count decreased	1	1	4	4	0
	Mucositis oral	1	1	0	0	0
	Nausea	1	1	0	0	0
	Neutrophil count decreased	0	0	2	1	0
	Oral hemorrhage	0	1	0	0	0
	Platelet count decreased	3	3	2	2	0
	Rash	2	0	0	0	0
	Respiratory, thoracic and mediastinal disorders	0	3	0	0	0
	Sinus tachycardia	2	1	0	0	0
	Urinary frequency	1	0	0	0	0
	Vomiting	1	1	0	0	0
	Weight loss	1	1	0	0	0
	White blood cell decreased	1	1	1	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 14: Adverse events for patient 025

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
025	Anemia	2	6	1	0	0
	Aspartate aminotransferase increased	1	0	0	0	0
	Blood and lymphatic system disorders	2	0	0	0	0
	Chills	0	2	0	0	0
	Creatinine increased	1	0	0	0	0
	Delirium	0	1	0	0	0
	Diarrhea	0	2	0	0	0
	Fever	1	0	0	0	0
	Generalized muscle weakness	0	1	0	0	0
	Hypoalbuminemia	2	1	0	0	0
	Hypocalcemia	2	0	0	0	0
	Hyponatremia	2	2	2	0	0
	Hypoxia	0	1	0	0	0
	Insomnia	2	0	0	0	0
	Investigations	0	1	0	0	0
	Lung infection	1	0	0	0	0
	Lymphocyte count decreased	1	2	0	2	0
	Lymphocyte count increased	0	2	0	0	0
	Nausea	0	2	0	0	0
	Nervous system disorders	0	1	0	0	0
	Neutrophil count decreased	1	0	0	1	0
	Platelet count decreased	3	3	0	1	0
	Seizure	1	0	0	0	0
	Sinus tachycardia	1	0	0	0	0
	Vomiting	0	2	0	0	0
	White blood cell decreased	1	5	0	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 15: Adverse events for patient 030

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
030	Alanine aminotransferase increased	2	0	0	0	0
	Hyperthyroidism	1	0	0	0	0
	Pain of skin	1	0	0	0	0
	Platelet count decreased	1	0	0	0	0
	Rash	1	0	0	0	0

Note:

Possible, Probable, or Definite Attribution Only

Table 16: Adverse events for patient 031

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
031	Anemia	0	2	4	0	0
	Anorexia	0	1	0	0	0
	Bullous dermatitis	0	1	0	0	0
	Creatinine increased	0	1	0	0	0
	Diarrhea	1	0	0	0	0
	Dyspnea	0	1	0	0	0
	Hematuria	1	0	0	0	0
	Hyperkalemia	0	0	0	1	0
	Hyponatremia	2	0	0	0	0
	Leukocytosis	0	0	1	0	0
	Lymphocyte count decreased	0	3	2	2	0
	Lymphocyte count increased	0	1	0	0	0
	Nausea	1	0	0	0	0
	Neutrophil count decreased	0	1	0	0	0
	Platelet count decreased	5	1	1	1	0
	Rash	1	0	0	0	0
	Weight loss	0	1	0	0	0
	White blood cell decreased	3	0	1	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 17: Adverse events for patient 032

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
032	Alanine aminotransferase increased	1	0	0	0	0
	Alkaline phosphatase increased	2	0	0	0	0
	Anemia	2	5	2	0	0
	Aspartate aminotransferase increased	2	0	0	0	0
	Cough	1	0	0	0	0
	Fever	3	2	0	0	0
	Hypercalcemia	1	1	0	0	0
	Hypermagnesemia	2	0	0	0	0
	Hypoalbuminemia	1	1	0	0	0
	Hypocalcemia	1	1	0	0	0
	Hypophosphatemia	0	1	0	0	0
	Lymphocyte count decreased	0	0	2	1	0
	Nausea	2	0	0	0	0
	Neutrophil count decreased	0	2	0	1	0
	Platelet count decreased	2	1	0	0	0
	White blood cell decreased	3	1	1	1	0

Note:

Possible, Probable, or Definite Attribution Only

Table 18: Adverse events for patient 033

		Grade				
Seq No.	CDUS/CTCAE Toxicity Type Code	1	2	3	4	5
033	Alkaline phosphatase increased	2	0	0	0	0
	Anemia	0	3	3	0	0
	Fever	0	1	0	0	0
	Hyperkalemia	2	0	0	0	0
	Hypermagnesemia	1	0	0	0	0
	Hypocalcemia	0	0	1	0	0
	Hyponatremia	2	0	2	1	0
	Lymphocyte count decreased	0	0	2	4	0
	Nausea	1	0	0	0	0
	Platelet count decreased	2	0	1	0	0
	Proteinuria	1	0	0	0	0
	Rash	1	0	0	0	0
	White blood cell decreased	1	0	0	1	0

Note:

Possible, Probable, or Definite Attribution Only

Appendix 2: Gating schema for flow cytometry of TIL cultures



Appendix 2: Gating schema for flow cytometry of TIL cultures



Appendix 2: Gating schema for flow cytometry of TIL cultures



Appendix 2: Gating schema for flow cytometry of TIL cultures